GSK has received approval for its Blenrep treatment for relapsed or refractory multiple myeloma from the Ministry of Health, Labour and Welfare in Japan. This approval follows positive results from two pivotal phase III trials, Dreamm-7 and Dreamm-8, which demonstrated significant advancements in treatment outcomes for patients.
This will be welcome news to holders of GSK shares (LON: GSK), having seen a 21.24% decline in the price over the past 12 months.
In the Dreamm-7 trial, Blenrep was combined with bortezomib and dexamethasone (BVd). This combination showed improved overall survival rates and significant progression-free survival compared to standard care. The Dreamm-8 trial evaluated Blenrep with pomalidomide and dexamethasone (BPd), where similar benefits were observed in progression-free survival.
Both trials underscored the potential of these Blenrep combinations to redefine treatment outcomes. Hesham Abdullah, GSK's Senior Vice President and Global Head of Oncology at R&D, emphasized the impact these results could have on patient care.
An additional benefit of the Blenrep treatment is its in-office administration, making it convenient for healthcare providers and patients.
This development marks a significant milestone for GSK, highlighting its ongoing commitment to advancing cancer therapies and improving patient outcomes in oncology.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
